Related references
Note: Only part of the references are listed.A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood
K. Oberg et al.
ANNALS OF ONCOLOGY (2020)
Plasma Pancreastatin Predicts the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel
Eugene A. Woltering et al.
PANCREAS (2019)
NCCN Guidelines® Insights Neuroendocrine and Adrenal Tumors, Version 2.2018 Featured Updates to the NCCN Guidelines
Manisha H. Shah et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
The Distal Predilection of Small Bowel Neuroendocrine Tumors
Kendall J. Keck et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors
David Strosberg et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
The NETest The Clinical Utility of Multigene Blood Analysis - in the Diagnosis and Management of Neuroendocrine Tumors
Irvin M. Modlin et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2018)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
Kjell Oberg et al.
NEUROENDOCRINOLOGY (2017)
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors
Jonathan R. Strosberg et al.
PANCREAS (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms
Irvin M. Modlin et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Elevated Plasma Pancreastatin, but Not Chromogranin A, Predicts Survival in Neuroendocrine Tumors of the Duodenum
Eugene A. Woltering et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2016)
Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors
Tahsin M. Khan et al.
PANCREAS (2016)
Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
Jessica E. Maxwell et al.
SURGERY (2016)
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
Kjell Oberg et al.
ENDOCRINE CONNECTIONS (2016)
Pancreastatin Predicts Survival in Neuroendocrine Tumors
Scott K. Sherman et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood
Irvin M. Modlin et al.
PLOS ONE (2013)
Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
George Kanakis et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
Limitations of Chromogranin A in clinical practice
Vincenzo Marotta et al.
BIOMARKERS (2012)
A Prospective Evaluation of the Effect of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans
Daniel Raines et al.
PANCREAS (2012)
Effect of Proton-Pump Inhibitor Therapy on Serum Chromogranin A Level
Istvan Pregun et al.
DIGESTION (2011)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne E. Pavel et al.
LANCET (2011)
Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study
Delphine Vezzosi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2011)
Chromogranin A-Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Irvin M. Modlin et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Development of a Highly Sensitive and Specific Carboxy-Terminal Human Pancreastatin Assay to Monitor Neuroendocrine Tumor Behavior
Thomas M. O'Dorisio et al.
PANCREAS (2010)
Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin
Victor Sanchez-Margalet et al.
REGULATORY PEPTIDES (2010)
Small Bowel Cancer in the United States Changes in Epidemiology, Treatment, and Survival Over the Lost 20 Years
Karl Y. Bilimoria et al.
ANNALS OF SURGERY (2009)
A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours
R. L. Stronge et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2008)
A comparison between three commercial kits for chromogranin A measurements
M Stridsberg et al.
JOURNAL OF ENDOCRINOLOGY (2003)
Mechanisms of disease - The chromogranin-secretogranin family.
L Taupenot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
